clinical study

Edesa Biotech (EDSA.Q) announced positive results today from its Phase 2 portion of an ongoing Phase 2/3 clinical study. This study is intended to evaluate EB05, the Company’s monoclonal…
Protagonist Therapeutics (PTGX.Q) announced the receipt of verbal communication from the U.S. Food and Drug Administration (FDA) that the Company’s clinical studies for rusfertide have been placed on a…
Bioasis Technologies (BTI.V) announced positive results today from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis (MS). “These…
Histogen (HSTO.Q), and its partner Amerimmune, today announced top-line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy….